We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Vicotex

Download Mobile App




Inactivation of the Cdk4 Gene Halts Tumor Growth

By Biotechdaily staff writers
Posted on 25 Nov 2002
Researchers studying the genetic basis for cancer development have found that expression of a gene called Cdk4 is essential for Ras-induced cancer development, regardless of the status of the p53 tumor suppressor gene or the presence of another frequently mutated tumor-suppressor gene, Ink4a/Arf. More...
Their findings were published in the November 15, 2002, issue of Genes and Development.

Investigators from the University of Illinois College of Medicine (Chicago, USA; www.uic.edu) genetically engineered mouse cells to lack Cdk4 in order to determine its role in tumorigenesis. They found that while Cdk4-deficient cells grew and divided normally under standard conditions, once the Ras oncogene was activated, these cells retreated into a state of senescence that was not tumorigenic. Ras-expressing Cdk4-deficient cells also entered senescence when either the p53 or Ink4a/Arf tumor suppressor gene was inactivated. These findings indicated that Cdk4 was required for tumorigenesis even when commonly mutated tumor suppressor genes were nonfunctional.

"We found that if you knock out a single gene called Cdk4, you can still make cells cancer resistant, even if their tumor-suppressor defense mechanism is deficient,” explained senior author Dr. Hiroaki Kiyokawa, assistant professor of molecular genetics at the University of Illinois College of Medicine. "Cells still go into senescence.”

Since about 30% of human tumors display an activated Ras oncogene, the deliberate suppression of Cdk4 activity may provide an alternate stratagem for regulation of the cell growth cycle and prevention of tumorigenesis.



Related Links:
University of Illinois, Chicago

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
New
MR-proADM Test
B•R•A•H•M•S MR-proADM KRYPTOR test
New
Fully Automated Urinalysis System
DxU 1800 Fully Automated Urinalysis System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Alzheimer’s pathology can start 15 to 20 years before symptoms, and validated tools that reach patients earlier help pave the way for earlier detection. (Image Credit: Adobe Stock)

Alzheimer’s Blood Test Becomes First FDA-Cleared Option for Adults as Young as 40

C2N Diagnostics’ PrecivityAD2 blood test was cleared by the U.S. Food and Drug Administration (FDA) on August 20, 2026, for adults as young as 40 who are experiencing signs of cognitive impairment, according... Read more

Pathology

view channel
Image: Adrenal gland tumor stained with hematoxylin and eosin (top) and CYP11B2 (bottom) (Photo courtesy of Christofer Juhlin)

Simple Immunohistochemical Size Ratio Improves Classification of Primary Aldosteronism

Primary aldosteronism is a common but underdiagnosed cause of hypertension, in which excess aldosterone promotes salt retention and raises blood pressure. Identifying the dominant source of hormone overproduction... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.